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Hyperimmune serum 
from healthy vaccinated 
individuals for Ebola 
virus disease?
As highlighted by Rajesh Gupta 
(October issue),1 strategies for 
developing treatments for Ebola virus 
disease (EVD) need to be rethought. 
New treatments have to be safe and 
effective, and in this sense testing 
already-approved drugs for a new 
indication is a good approach. With 
the same philosophy in mind, there are 
old approaches that could be saving 
lives in the current outbreak of EVD.
Hyperimmune serum from con-
valescent patients is regarded by 
WHO as a potential treatment for 
EVD.2 The rationale for convalescent 
serum treatment is provided by 
limited experiences during the Ebola 
outbreak in the Democratic Republic 
of Congo in 19953 and also from tests 
in non-human primates.4 Addition-
ally, con valescent serum has been used 
in Spain and other countries to treat 
patients with EVD during the current 
outbreak. Nonetheless, obtaining 
convalescent serum is a diﬃ  cult task 
and not free of risk. The logistics of 
identifying survivors is not easy. Also, 
blood from survivors needs to be 
tested to rule out presence of virus.
Vaccinated individuals might 
represent a safer source of hyper-
immune serum. Two vaccine 
candidates will be tested soon in 
west Africa.5 If serum from vaccinated 
individuals has neutralising activity 
against the virus in cell models, this 
serum could be used as adjuvant 
therapy for EVD. In parallel, animal 
models could be developed to 
compare hyperimmune serum 
against a placebo. In the current 
scenario, this strategy could offer 
some hope to patients with this 
devastating disease. 
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